Peptic Ulcers – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Peptic Ulcers – Pipeline Review, H2 2016’, provides an overview of the Peptic Ulcers pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Peptic Ulcers, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Peptic Ulcers and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Peptic Ulcers

The report reviews pipeline therapeutics for Peptic Ulcers by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Peptic Ulcers therapeutics and enlists all their major and minor projects

The report assesses Peptic Ulcers therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Peptic Ulcers

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Peptic Ulcers

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Peptic Ulcers pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Astellas Pharma Inc

Boryung Pharmaceutical Co Ltd

ChoDang Pharm Co Ltd

Daewoong Pharmaceutical Co Ltd

Kukje Pharmaceutical Industry Co Ltd

RaQualia Pharma Inc

Sequella Inc

Sinil Pharmaceutical Co Ltd

XuanZhu Pharma Co Ltd

Yooyoung Pharmaceutical Co Ltd

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

Peptic Ulcers Overview 7

Therapeutics Development 8

Pipeline Products for Peptic Ulcers - Overview 8

Peptic Ulcers - Therapeutics under Development by Companies 9

Peptic Ulcers - Pipeline Products Glance 10

Clinical Stage Products 10

Early Stage Products 11

Peptic Ulcers - Products under Development by Companies 12

Peptic Ulcers - Companies Involved in Therapeutics Development 13

Astellas Pharma Inc 13

Boryung Pharmaceutical Co Ltd 14

ChoDang Pharm Co Ltd 15

Daewoong Pharmaceutical Co Ltd 16

Kukje Pharmaceutical Industry Co Ltd 17

RaQualia Pharma Inc 18

Sequella Inc 19

Sinil Pharmaceutical Co Ltd 20

XuanZhu Pharma Co Ltd 21

Yooyoung Pharmaceutical Co Ltd 22

Peptic Ulcers - Therapeutics Assessment 23

Assessment by Monotherapy Products 23

Assessment by Combination Products 24

Assessment by Target 25

Assessment by Mechanism of Action 27

Assessment by Route of Administration 29

Assessment by Molecule Type 30

Drug Profiles 31

(ecabet + ranitidine) - Drug Profile 31

Product Description 31

Mechanism Of Action 31

R&D Progress 31

(lansoprazole + omeprazole) - Drug Profile 32

Product Description 32

Mechanism Of Action 32

R&D Progress 32

anaprazole sodium - Drug Profile 33

Product Description 33

Mechanism Of Action 33

R&D Progress 33

ASP-6537 - Drug Profile 34

Product Description 34

Mechanism Of Action 34

R&D Progress 34

BGC-001 - Drug Profile 35

Product Description 35

Mechanism Of Action 35

R&D Progress 35

cholesteryl glucoside - Drug Profile 36

Product Description 36

Mechanism Of Action 36

R&D Progress 36

DWJ-1386 - Drug Profile 37

Product Description 37

Mechanism Of Action 37

R&D Progress 37

DWJ-206 - Drug Profile 38

Product Description 38

Mechanism Of Action 38

R&D Progress 38

KJ-14001 - Drug Profile 39

Product Description 39

Mechanism Of Action 39

R&D Progress 39

PMKS-005 - Drug Profile 40

Product Description 40

Mechanism Of Action 40

R&D Progress 40

RQ-00000774 - Drug Profile 41

Product Description 41

Mechanism Of Action 41

R&D Progress 41

SI-001002 SR - Drug Profile 42

Product Description 42

Mechanism Of Action 42

R&D Progress 42

Small Molecule to Inhibit Potassium Transporting ATPase Alpha Chain 1 Inhibitor for Peptic Ulcers and Reflux Esophagitis - Drug Profile 43

Product Description 43

Mechanism Of Action 43

R&D Progress 43

Small Molecules for Gastric Ulcers - Drug Profile 44

Product Description 44

Mechanism Of Action 44

R&D Progress 44

SQ-109 - Drug Profile 45

Product Description 45

Mechanism Of Action 45

R&D Progress 45

YYD-601 - Drug Profile 48

Product Description 48

Mechanism Of Action 48

R&D Progress 48

Peptic Ulcers - Dormant Projects 49

Peptic Ulcers - Discontinued Products 51

Peptic Ulcers - Product Development Milestones 52

Featured News & Press Releases 52

Jul 17, 2013: Sihuan Pharmaceutical Secures SFDA Approval for Anaprazole Sodium Category

1.1 New Drug Clinical Studies 52

Dec 06, 2010: Sequella Wins FDA Approval To Begin Phase II Trial Of SQ109 In Helicobacter pylori-Associated Duodenal Ulcers 53

Mar 01, 2010: AstraZeneca Provides An Update On The Status Of Its Arrangements With Merck 53

Jan 07, 2010: AstraZeneca Reaches Agreements With Teva Pharmaceuticals Regarding Nexium And Prilosec US Patent Litigations 54

Apr 15, 2008: AstraZeneca Settles US Nexium Patent Litigation with Ranbaxy 54

Feb 28, 2008: AstraZeneca Provides An Update on the Status of its Arrangements With Merck & Co., Inc. 55

Dec 10, 2007: FDA Concludes There Is No Increased Risk Of Cardiac Events For Patients Treated With Omeprazole And NEXIUM (Esomeprazole Magnesium) 55

Jun 01, 2007: AstraZeneca’s Prilosec Patents Upheld By Court 56

Dec 12, 2003: Astrazeneca Prilosec Patents Upheld by Federal Appeals Court 56

Appendix 57

Methodology 57

Coverage 57

Secondary Research 57

Primary Research 57

Expert Panel Validation 57

Contact Us 57

Disclaimer 58

List of Tables

List of Tables

Number of Products under Development for Peptic Ulcers, H2 2016 8

Number of Products under Development by Companies, H2 2016 9

Comparative Analysis by Clinical Stage Development, H2 2016 10

Comparative Analysis by Early Stage Development, H2 2016 11

Products under Development by Companies, H2 2016 12

Peptic Ulcers – Pipeline by Astellas Pharma Inc, H2 2016 13

Peptic Ulcers – Pipeline by Boryung Pharmaceutical Co Ltd, H2 2016 14

Peptic Ulcers – Pipeline by ChoDang Pharm Co Ltd, H2 2016 15

Peptic Ulcers – Pipeline by Daewoong Pharmaceutical Co Ltd, H2 2016 16

Peptic Ulcers – Pipeline by Kukje Pharmaceutical Industry Co Ltd, H2 2016 17

Peptic Ulcers – Pipeline by RaQualia Pharma Inc, H2 2016 18

Peptic Ulcers – Pipeline by Sequella Inc, H2 2016 19

Peptic Ulcers – Pipeline by Sinil Pharmaceutical Co Ltd, H2 2016 20

Peptic Ulcers – Pipeline by XuanZhu Pharma Co Ltd, H2 2016 21

Peptic Ulcers – Pipeline by Yooyoung Pharmaceutical Co Ltd, H2 2016 22

Assessment by Monotherapy Products, H2 2016 23

Assessment by Combination Products, H2 2016 24

Number of Products by Stage and Target, H2 2016 26

Number of Products by Stage and Mechanism of Action, H2 2016 28

Number of Products by Stage and Route of Administration, H2 2016 29

Number of Products by Stage and Molecule Type, H2 2016 30

Peptic Ulcers – Dormant Projects, H2 2016 49

Peptic Ulcers – Dormant Projects (Contd..1), H2 2016 50

Peptic Ulcers – Discontinued Products, H2 2016 51

List of Figures

List of Figures

Number of Products under Development for Peptic Ulcers, H2 2016 8

Number of Products under Development by Companies, H2 2016 9

Comparative Analysis by Clinical Stage Development, H2 2016 10

Assessment by Monotherapy Products, H2 2016 23

Number of Products by Targets, H2 2016 25

Number of Products by Stage and Targets, H2 2016 25

Number of Products by Top 10 Mechanism of Actions, H2 2016 27

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 27

Number of Products by Stage and Routes of Administration, H2 2016 29

Number of Products by Stage and Molecule Types, H2 2016 30

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports